(MedPage Today) — Patients with advanced non-small cell lung cancer who received immunochemotherapy in the morning or early afternoon had better survival outcomes compared with patients who received treatment later in the day, a phase III randomized…
Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/119696
Author :
Publish date : 2026-02-02 20:36:00
Copyright for syndicated content belongs to the linked Source.
